Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study

作者：Shun Lü, Lin Wu, Qiming Wang, Ziping Wang, Dongqing Lv, Rui Ma, Bo Zhu, Ngoc Van Tran, Liyan Jiang, Kejun Nan, К. К. Лактионов, Stephen R. Clarke, Minghao Song, Helen Mann, Yinglei Liu, Xiaojin Shi, Yi‐Long Wu · 发表于：Journal of Thoracic Oncology · 年份：2024 · DOI：10.1016/j.jtho.2024.10.024 · 被引用次数：9 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Esophageal Cancer Research and Treatment